Federal Government Agency Funds Research by Company to Improve CBD Production in Genetically Engineered Yeast

librede_logo

There is little doubt that cannabidiol (CBD) has medicinal benefits.  Sanjay Gupta brought this into the mainstream in 2013 with his famous reversal, and, three years later, GW Pharma (NASDAQ: GWPH) has completed three late-stage FDA clinical trials for Epidiolex demonstrating the safety and efficacy of CBD in treating seizures in rare forms of childhood epilepsy. Biotech companies Insys Therapeutics (NASDAQ: INSY) and Zynerba Pharma (NASDAQ: ZYNE) are developing synthetic CBD medicines as well.

While most are familiar with these efforts, California-based Librede and several other companies are pursuing ways to produce cannabinoids, like CBD, from alternative sources, such as yeast. We raised this issue earlier this year, suggesting that biosynthesis could radically change the cannabis industry, as it could prove to be a more economic way of production.

As demand for cannabinoids increases we must find an environmentally and economically sustainable way for their production. Large scale agricultural production is environmentally destructive, requiring huge amounts of land, water, fertilizers, pesticide and energy. Our yeast-based system is superior to agricultural production with respect to all of these areas.

jason-poulos-libredeJason Poulos, Librede CEO

Earlier this year, Librede received a $221K Small Business Innovative Research (SBIR) grant from the National Center for Complementary & Integrative Health (NCCIH) of the National Institutes of Health (NIH) to develop its biosynthetic cannabinoid production technology. NIH is an agency of the the United States Department of Health and Human Services and supports health research. Today, the company announced a follow-on grant to study improving CBD production in genetically engineered yeast, though the size of the grant wasn’t disclosed.

It is straightforward to modify the engineered yeast to produce a number of different cannabinoids. Many of these cannabinoids are produced in plants at such low levels that it is infeasible to produce them agriculturally. We are very excited to expand the range of cannabinoids produced for use in pharmaceutical studies.

anthony-farina-libredeDr. Anthony Farina, Librede Chief Scientific Officer
Exclusive article by Alan Brochstein, CFA
Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online communities 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter